The health department is pushing forward with its plans to roll out a combination antiretroviral (ARV) drug despite concerns that it may cause birth defects. This month pharmaceutical companies were awarded a three-year tender to provide the state with triple combination ARVs, the bulk of which are tenofovir/emtricitabane/efavirenz and dolutegravir/lamivudine/tenofovir (DLT)." Department spokesperson Popo Maja said the department decided to provide DLT while it waited for the results of an ongoing study. "This drug does present a number of advantages over the current treatment regimen in other patient groups, except women of child-bearing age. The risks relating to mothers and their infants have not been confirmed through a proper study, he said. Women of child-bearing age will be excluded until the results are finalised. A study conducted in Botswana found four cases of neural tube defects in the babies of 426 women who conceived while taking the drug. Neural tube defects affect th...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now